U.S. Markets open in 5 hrs 39 mins

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
458.24-3.13 (-0.68%)
At close: 4:00PM EDT
People also watch

    BMY and MRK promising blockbuster PD1 Inhibitor Keytruda and Opdivo beginning combination trials with NWBO DC-Vax-L.
    NWBO shares already beginning to move up now as investors realize major positive announcements from 10 year brain cancer phase III trial are likely next week at ASCO.

    Company already announced in February that it had met the Primary Progression Free Survival Endpoint and that not yet for Overall Survival but expected in this current timeframe.

    Shares have been under extreme selling pressure from negative press by the usual short seller advocates.

    Expected news could cause EXTREME PRICE INCREASE.

    NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached
    BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Compa
  • We must interpret a bad temper as a sign of inferiority. http://dataunion.tistory.com/3065

    Regeneron Pharmaceuticals Inc NASDAQ : REGN Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.9 In other words, the correlation coefficient of the other stock
  • Now that we are doing well (I am speaking to longs on Regeneron), I guess the immediate questions how much has this great climb upward already been built in or will it continue to climb on the news yesterday about rheumatoid arthritis. I am thinking that it will climb more now because both Dupixent and Salumibab have great potential. Thoughts are welcome as always.
  • sanofi is the player.

    they're in there buying stock almost every day. and e wet time they ask to increase their position management says ok. long term this stock is going much higher, and I don't mean $535.
  • thanks Martin
  • It has a pipeline, obviously excellent discovery labs, why can't REGN become a MRK, PFE or JNJ?
  • Not a great earnings report to say the least but there is so much good news ahead with two potential blockbuster drugs even if Praulent continues to falter. I think it's going down big time today and maybe for awhile before going up in the way we hope and I anticipate over the next four or five months. Any thoughts are welcome.
  • I see a $500 in the next 6-8 months
  • We are having a nice day today lets hope we have good follow through next week with emphasis next Thursday morning earnings and maybe some other news about these lawsuits. Have a great weekend.
  • Overall I think we will see upside for REGN in the short-term. Perhaps a pullback next day or so could occur I suppose but are yall also seeing a further leg higher? Yo you should really check out awesome-STOCKS, they seem on point with their stocks.
  • Nice little spike in the last 15 minuets. Looks like a potential breakout ahead of earnings. Lets hope it holds and everything they say is very positive. Good luck to us all.
  • "Better than feared" Don't know why I click on these articles.
  • Anyone have thoughts about earnings? I'm debating about adding to my already very large position because I think that in two years it will be much higher but can't figure out whether we will some selling after earnings.
  • 400+ Coming with next week's earnings. Pow!
  • Kramer says that Sanofi should just merge with RGEN. I agree just tare up the agreement about ownership restriction and get it done.
  • REGN gets Thumbs Up from ETFCycle.com


    ETF Cycle
  • REGN just got bumped up from 3 (hold) to 2 (buy) from Zacks today. This is a good sign for the next few months.
  • Amgen: If you can't beat em, rob em!
  • Positive REGN reference in Barron's article over the weekend!